Cannabis Ruderalis

Fibromyalgia
Other namesFibromyalgia syndrome (FMS)
Widespread Pain Index Areas with numbers.svg
The location of the 19 pain areas for the Widespread Pain Index of fibromyalgia
Pronunciation
SpecialtyPsychiatry, rheumatology, neurology[2]
SymptomsWidespread pain, feeling tired, sleep problems[3][4]
Usual onsetMiddle age[5]
DurationLong term[3]
CausesUnknown[4][5]
Diagnostic methodBased on symptoms after ruling out other potential causes[4][5]
Differential diagnosisPolymyalgia rheumatica, rheumatoid arthritis, osteoarthritis, thyroid disease[6]
TreatmentSufficient sleep and exercise[5]
MedicationDuloxetine, milnacipran, pregabalin, gabapentin[5][7]
PrognosisNormal life expectancy[5]
Frequency2–8%[4]

Fibromyalgia (FM) is a medical condition defined by the presence of chronic widespread pain, fatigue, waking unrefreshed, cognitive symptoms, lower abdominal pain or cramps, and depression.[8] Other symptoms include insomnia[9] and a general hypersensitivity.[10][11]

The cause of fibromyalgia is unknown, but is believed to involve a combination of genetic and environmental factors.[4] Environmental factors may include psychological stress, trauma, and certain infections.[4] The pain appears to result from processes in the central nervous system and the condition is referred to as a "central sensitization syndrome".[4][12]

The treatment of fibromyalgia is symptomatic[13] and multidisciplinary.[14] The European Alliance of Associations for Rheumatology strongly recommends aerobic and strengthening exercise.[14] Weak recommendations are given to mindfulness, psychotherapy, acupuncture, hydrotherapy, and meditative exercise such as qigong, yoga, and tai chi.[14] The use of medication in the treatment of fibromyalgia is debated,[15][14] although antidepressants can improve quality of life.[16] The medications duloxetine, milnacipran, or pregabalin have been approved by the US Food and Drug Administration (FDA) for the management of fibromyalgia. Other common helpful medications include serotonin-noradrenaline reuptake inhibitors (SNRI), non-steroidal anti-inflammatory drugs (NSAIDs), and muscle relaxants.[17] Q10 coenzyme and vitamin D supplements may improve pain and quality of life.[18] While fibromyalgia is persistent in nearly all patients, it does not result in death or tissue damage.[15][19]

Fibromyalgia is estimated to affect 2–4% of the population.[20] Women are affected about twice as often as men.[4][20] Rates appear similar in different areas of the world and among different cultures.[4] Fibromyalgia was first defined in 1990, with updated criteria in 2011,[4] 2016,[8] and 2019.[11] The term "fibromyalgia" is from New Latin fibro-, meaning "fibrous tissues", Greek μυώ myo-, "muscle", and Greek άλγος algos, "pain"; thus, the term literally means "muscle and fibrous connective tissue pain".[21]

Classification[edit]

Fibromyalgia is classed as a disorder of pain processing due to abnormalities in how pain signals are processed in the central nervous system.[22] The International Classification of Diseases (ICD-11) lists fibromyalgia as an included in the category of "Chronic widespread pain", code MG30.01.[23]

Signs and symptoms[edit]

Fibromyalgia symptoms.svg

The defining symptoms of fibromyalgia are chronic widespread pain, fatigue, and sleep disturbance.[11] Other symptoms may include heightened pain in response to tactile pressure (allodynia),[11] cognitive problems,[11] musculoskeletal stiffness,[11] environmental sensitivity,[11] hypervigilance,[11] sexual dysfunction,[24] and visual symptoms.[25]

Pain[edit]

Fibromyalgia is predominantly a chronic pain disorder.[11] According to the NHS, widespread pain is one major symptom, which could feel like: an ache, a burning sensation, or a sharp, stabbing pain.[26]

Fatigue[edit]

Fatigue is one of the defining symptoms of fibromyalgia.[11] Patients may experience physical or mental fatigue. Physical fatigue can be demonstrated by a feeling of exhaustion after exercise or by a limitation in daily activities.[11] Due to the predominance of fatigue, fibromyalgia bears a similarity to chronic fatigue syndrome.[27]

Sleep problems[edit]

Sleep problems are a core symptom in fibromyalgia.[11] These include a difficulty to fall asleep or stay asleep, awakening while sleeping and waking up feeling unrefreshed.[11] A meta-analysis compared objective and subjective sleep metrics in people with fibromyalgia and healthy people. Individuals with fibromyalgia had lower sleep quality and efficiency, as well as longer wake time after sleep start, shorter sleep duration, lighter sleep, and greater trouble initiating sleep when objectively assessed, and more difficulty initiating sleep when subjectively assessed.[9]

Cognitive problems[edit]

Many people with fibromyalgia experience cognitive problems (known as "fibrofog" or "brainfog"). One study found that approximately 50% of fibromyalgia patients had subjective cognitive dysfunction and that it was associated with higher levels of pain and other fibromyalgia symptoms.[28] The American Pain Society recognizes these problems as a major feature of fibromyalgia, characterized by trouble concentrating, forgetfulness and disorganized or slow thinking.[11] Studies have shown that fibromyalgia patients exhibit problems with short[29]- and long-term memory, short-term memory consolidation,[29] working memory,[30] impaired speed of performance,[29] inability to multi-task, cognitive overload,[29] and diminished attention span. About 75% of fibromyalgia patients report significant problems with concentration, memory, and multitasking.[31] A 2018 meta-analysis found that the largest differences between fibromyalgia patients and healthy subjects were for inhibitory control, memory, and processing speed.[31] It is hypothesized that the increased pain compromises attention systems, resulting in cognitive problems.[31]

Hypersensitivity[edit]

In addition to a hypersensitivity to pain, patients with fibromyalgia show hypersensitivity to other stimuli,[10] such as bright lights, loud noises, perfumes and cold.[11] A review article found that they have a lower cold pain threshold.[32] Other studies documented an acoustic hypersensitivity.[33]

Risk factors[edit]

The cause of fibromyalgia is unknown. However, several risk factors, genetic and environmental, have been identified.

Genetics[edit]

Genetics play a major role in fibromyalgia, and may explain up to 50% of the disease susceptibility.[34] Fibromyalgia is potentially associated with polymorphisms of genes in the serotoninergic,[35] dopaminergic[35] and catecholaminergic systems.[35] Several genes have been suggested as candidates for susceptibility to fibromyalgia. These include SLC64A4,[34] TRPV2,[34] MYT1L,[34] NRXN3,[34] and the 5-HT2A receptor 102T/C polymorphism.[36] The heritability of fibromyalgia is estimated to be higher in patients younger than 50.[37]

Neuropathic pain and major depressive disorder often co-occur with fibromyalgia – the reason for this comorbidity appears to be due to shared genetic abnormalities, which leads to impairments in monoaminergic, glutamatergic, neurotrophic, opioid and proinflammatory cytokine signaling. In these vulnerable individuals, psychological stress or illness can cause abnormalities in inflammatory and stress pathways that regulate mood and pain. Eventually, a sensitization and kindling effect occurs in certain neurons leading to the establishment of fibromyalgia and sometimes a mood disorder.[38]

Nervous system[edit]

Stress[edit]

A woman feeling stress
A woman feeling stress

Stress may be an important precipitating factor in the development of fibromyalgia.[39] A 2021 meta-analysis found psychological trauma to be strongly associated with fibromyalgia.[40] People who suffered abuse in their lifetime were three times more likely to have fibromyalgia, people who suffered medical trauma or other stressors in their lifetime were about twice as likely.[40]

Some authors have proposed that, because exposure to stressful conditions can alter the function of the hypothalamic-pituitary-adrenal (HPA) axis, the development of fibromyalgia may stem from stress-induced disruption of the HPA axis.[41][42]

Several studies have linked fibromyalgia with a previous "hyperactive" lifestyle, where a person goes beyond his or her limits and neglects basic bodily needs such as food and rest.[unreliable medical source?][43] This lifestyle has been hypothesized to increase the allostatic load and contribute to a state of physical deconditioning.[unreliable medical source?][44]

Fibromyalgia is frequently comorbid with stress-related disorders such as chronic fatigue syndrome, posttraumatic stress disorder, irritable bowel syndrome and depression.[45]

Personality[edit]

Although some have suggested that fibromyalgia patients are more likely to have specific personality traits, when depression is statistically controlled for, it appears that their personality is no different than that of people in the general population.[46]

Lifestyle[edit]

Poor lifestyles including being a smoker, obesity and inactivity may increase the risk of an individual developing fibromyalgia.[47]

Sleep disturbances[edit]

Impaired sleep is a risk factor for fibromyalgia.[4] In 1975, Moldofsky and colleagues reported the presence of anomalous alpha wave activity (typically associated with arousal states) measured by electroencephalogram (EEG) during non-rapid eye movement sleep of "fibrositis syndrome".[48] By disrupting stage IV sleep consistently in young, healthy subjects, the researchers reproduced a significant increase in muscle tenderness similar to that experienced in "neurasthenic musculoskeletal pain syndrome" but which resolved when the subjects were able to resume their normal sleep patterns.[49] Mork and Nielsen used prospective data and identified a dose-dependent association between sleep problems and risk of fibromyalgia.[unreliable medical source?][50] Improving sleep quality can help people with fibromyalgia minimize pain.[51]

Non-celiac gluten sensitivity[edit]

Non-celiac gluten sensitivity (NCGS) may be an underlying cause of fibromyalgia-like symptoms but further research is needed.[52][53]

Other risk markers[edit]

Other risk markers for fibromyalgia include premature birth, female sex, cognitive influences, primary pain disorders, multiregional pain, infectious illness, hypermobility of joints, iron deficiency and small-fiber polyneuropathy.[54]

Pathophysiology[edit]

As of 2022, the pathophysiology of fibromyalgia has not yet been elucidated[55] and several theories have been suggested.

Nervous system[edit]

Pain processing abnormalities[edit]

Chronic pain can be divided into three categories. Nociceptive pain is pain caused by inflammation or damage to tissues. Neuropathic pain is pain caused by nerve damage. Nociplastic pain (or central sensitization) is less understood and is the common explanation of the pain experienced in fibromyalgia.[20][12][56] Because the three forms of pain can overlap, fibromyalgia patients may experience nociceptive (e.g., rheumatic illnesses) and neuropathic (e.g., small fiber neuropathy) pain, in addition to nociplastic pain.[20]

Nociplastic pain (central sensitization)[edit]

Nociplastic pain is caused by an altered function of pain-related sensory pathways in the periphery and the central nervous system, resulting in hypersensitivity.

Nociplastic pain is commonly referred to as "Nociplastic pain syndrome" because it is coupled with other symptoms.[20] These include fatigue, sleep disturbance, cognitive disturbance, hypersensitivity to environmental stimuli, anxiety, and depression.[20] Nociplastic pain is caused by either (1) increased processing of pain stimuli or (2) decreased suppression of pain stimuli at several levels in the nervous system, or both.[20]

Abnormalities in the ascending and descending pathways involved in processing pain have been observed in fibromyalgia. Fifty percent less stimulus is needed to evoke pain in those with fibromyalgia.[57] A proposed mechanism for chronic pain is sensitization of secondary pain neurons mediated by increased release of proinflammatory cytokines and nitric oxide by glial cells.[58][unreliable medical source?]

Neuropathic pain[edit]

An alternative hypothesis to nociplastic pain views fibromyalgia as a stress-related dysautonomia with neuropathic pain features.[59] This view highlights the role of autonomic and peripheral nociceptive nervous systems in the generation of widespread pain, fatigue, and insomnia.[60] The description of small fiber neuropathy in a subgroup of fibromyalgia patients supports the disease neuropathic-autonomic underpinning.[59] However, others claim that small fiber neuropathy occurs only in small group of those with fibromyalgia.[15]

Autonomic nervous system[edit]

Autonomic nervous system abnormalities have been observed in fibromyalgia.[61][62] These include decreased vasoconstriction response, increased drop in blood pressure, and worsening of symptoms in response to tilt table test.[57]

More specifically, some suggest that fibromyalgia is caused or maintained by a decreased vagal tone, which is indicated by low levels of heart rate variability,[39] signaling a heightened sympathetic response.[63] Accordingly, several studies show that clinical improvement is associated with an increase in heart rate variability.[64][63][65] Some examples of interventions that increase the heart rate variability and vagal tone are meditation, yoga, mindfulness and exercise.[39] Preliminary findings suggest that electrically stimulating the vagus nerve can potentially reduce fibromyalgia symptoms.[66]

Neurotransmitters[edit]

Some neurochemical abnormalities that occur in fibromyalgia also regulate mood, sleep, and energy, thus explaining why mood, sleep, and fatigue problems are commonly co-morbid with fibromyalgia.[22] Serotonin is the most widely studied neurotransmitter in fibromyalgia. It is hypothesized that an imbalance in the serotoninergic system may lead to the development of fibromyalgia.[67] There is also some data that suggests altered dopaminergic and noradrenergic signaling in fibromyalgia.[68] Supporting the monoamine related theories is the efficacy of monoaminergic antidepressants in fibromyalgia.[69][70][unreliable medical source?]

Neuroimaging[edit]

Neuroimaging studies have observed decreased levels of N-acetylaspartic acid (NAA) in the hippocampus of people with fibromyalgia, indicating decreased neuron functionality in this region. Altered connectivity and decreased grey matter of the default mode network,[71] the insula, and executive attention network have been found in fibromyalgia. Increased levels of glutamate and glutamine have been observed in the amygdala, parts of the prefrontal cortex, the posterior cingulate cortex, and the insula, correlating with pain levels in FM. Decreased GABA has been observed in the anterior insular in fibromyalgia. However, neuroimaging studies, in particular neurochemical imaging studies, are limited by methodology and interpretation.[72] Increased cerebral blood flow in response to pain was found in one fMRI study.[58] Findings of decreased blood flow in the thalamus and other regions of the basal ganglia correlating with treatment have been relatively consistent over three studies. Decreased binding of μ-opioid receptor have been observed; however, it is unknown if this is a result of increased endogenous binding in response to pain, or down regulation.[68]

Neuroendocrine system[edit]

Studies on the neuroendocrine system and HPA axis in fibromyalgia have been inconsistent. One study found fibromyalgia patients exhibited higher plasma cortisol, more extreme peaks and troughs, and higher rates of dexamethasone non-suppression. However, other studies have only found correlations between a higher cortisol awakening response and pain, and not any other abnormalities in cortisol.[57] Increased baseline ACTH and increase in response to stress have been observed, hypothesized to be a result of decreased negative feedback.[68]

Sleep[edit]

Disrupted sleep, insomnia, and poor-quality sleep occur frequently in fibromyalgia, and may contribute to pain by decreased release of IGF-1 and human growth hormone, leading to decreased tissue repair. Restorative sleep was correlated with improvement in pain-related symptoms.[57]

Immune system[edit]

Inflammation has been suggested to have role in the pathogenesis of fibromyalgia.[73] People with fibromyalgia tend to have higher levels of inflammatory cytokines IL-6,[74][75][67] and IL-8.[74][75][67] There are also increased levels of the pro-inflammatory cytokines IL-1 receptor antagonist.[74][75] Increased levels of pro-inflammatory cytokines may increase sensitivity to pain, and contribute to mood problems.[76] Anti-inflammatory interleukins such as IL-10 have also been associated with fibromyalgia.[67]

A repeated observation shows that autoimmunity triggers such as traumas and infections are among the most frequent events preceding the onset of fibromyalgia.[77] Neurogenic inflammation has been proposed as a contributing factor to fibromyalgia.[78]

Digestive system[edit]

Gut microbiome[edit]

Some fibromyalgia patients frequently report worsening or remission of symptoms in response to certain foods, but there is no consistent data to back up these claims. There is a growing hypothesis that leakage from the gut microbiome into the body can impact nervous system processes. The leakage can be of complete bacteria, components of microorganisms, or microbe-associated compounds.[unreliable medical source?][79] A 2020 review indicated that high quality evidence is lacking, but gut bacteria may play a role in fibromyalgia.[80] There is a bidirectional interplay between the gut and the nervous system. Therefore, the gut can effect the nervous system, but the nervous system can also effect the gut. Neurological effects mediated via the autonomic nervous system as well as the hypothalamic pituitary adrenal axis are directed to intestinal functional effector cells, which in turn are under the influence of the gut microbiota.[unreliable medical source?][79]

Gut-brain axis[edit]

The gut-brain axis, which connects the gut microbiome to the brain via the enteric nervous system, is another area of research. Fibromyalgia patients have less varied gut flora and altered serum metabolome levels of glutamate and serine,[81] implying abnormalities in neurotransmitter metabolism.[77] Microbiome variations in fibromyalgia have also been discovered in other research.[unreliable medical source?][79] However, it is still unclear if these changes have a direct role in the syndrome's pathophysiology or are only a predictor.[79]

Diagnosis[edit]

The location of the nine paired tender points that comprise the 1990 American College of Rheumatology criteria for fibromyalgia

There is no single pathological feature, laboratory finding, or biomarker that can diagnose fibromyalgia and there is debate over what should be considered diagnostic criteria and whether an objective diagnosis is possible.[54] In most cases, people with fibromyalgia symptoms may have laboratory test results that appear normal and many of their symptoms may mimic those of other rheumatic conditions such as arthritis or osteoporosis. The specific diagnostic criteria for fibromyalgia have evolved over time.

American College of Rheumatology 1990[edit]

The first widely accepted set of classification criteria for research purposes was elaborated in 1990 by the Multicenter Criteria Committee of the American College of Rheumatology. These criteria, which are known informally as "the ACR 1990", defined fibromyalgia according to the presence of the following criteria:

  • A history of widespread pain lasting more than three months – affecting all four quadrants of the body, i.e., both sides, and above and below the waist.
  • Tender points – there are 18 designated possible tender points (although a person with the disorder may feel pain in other areas as well).

The ACR criteria for the classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis but have later become the de facto diagnostic criteria in the clinical setting. A controversial study was done by a legal team looking to prove their client's disability based primarily on tender points and their widespread presence in non-litigious communities prompted the lead author of the ACR criteria to question now the useful validity of tender points in diagnosis.[82] Use of control points has been used to cast doubt on whether a person has fibromyalgia, and to claim the person is malingering.[83]

American College of Rheumatology 2010 provisional criteria[edit]

Widespread pain index (WPI) areas

In 2010, the American College of Rheumatology approved provisional revised diagnostic criteria for fibromyalgia that eliminated the 1990 criteria's reliance on tender point testing.[84] The revised criteria used a widespread pain index (WPI) and symptom severity scale (SSS) in place of tender point testing under the 1990 criteria. The WPI counts up to 19 general body areas[a] in which the person has experienced pain in the preceding week.[8] The SSS rates the severity of the person's fatigue, unrefreshed waking, cognitive symptoms, and general somatic symptoms,[b] each on a scale from 0 to 3, for a composite score ranging from 0 to 12.[8] The revised criteria for diagnosis were:

  • WPI ≥ 7 and SSS ≥ 5 OR WPI 3–6 and SSS ≥ 9,
  • Symptoms have been present at a similar level for at least three months, and
  • No other diagnosable disorder otherwise explains the pain.[84]: 607 

American College of Rheumatology 2016 revisions[edit]

In 2016, the provisional criteria of the American College of Rheumatology from 2010 were revised.[8] The new diagnosis required all of the following criteria:

  1. "Generalized pain, defined as pain in at least 4 of 5 regions, is present."
  2. "Symptoms have been present at a similar level for at least 3 months."
  3. "Widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9."
  4. "A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses."[8]

American Pain Society 2019[edit]

In 2019, the American Pain Society in collaboration with the U.S. Food and Drug Administration developed a new diagnostic system using two dimensions.[11] The first dimension included core diagnostic criteria and the second included common features. In accordance to the 2016 diagnosis guidelines, the presence of another medical condition or pain disorder does not rule out the diagnosis of fibromyalgia. Nonetheless, other conditions should be ruled out as the main explaining reason for the patient's symptoms. The core diagnostic criteria are:

  1. Multisite pain defined as six or more pain sites from a total of nine possible sites, for at least three months
  2. Moderate to severe sleep problems or fatigue, for at least three months

Common features found in fibromyalgia patients can assist the diagnosis process. These are tenderness (sensitivity to light pressure), dyscognition (difficulty to think), musculoskeletal stiffness, and environmental sensitivity or hypervigilance.[11]

Multidimensional assessment[edit]

Some research has suggested not to categorise fibromyalgia as a somatic disease or a mental disorder, but to use a multidimensional approach taking into consideration somatic symptoms, psychological factors, psychosocial stressors and subjective belief regarding fibromyalgia.[85] A review has looked at self-report questionnaires assessing fibromyalgia on multiple dimensions, including:[85]

Differential diagnosis[edit]

As of 2009, as many as two out of every three people who are told that they have fibromyalgia by a rheumatologist may have some other medical condition instead.[88] Fibromyalgia could be misdiagnosed in cases of early undiagnosed rheumatic diseases such as preclinical rheumatoid arthritis, early stages of inflammatory spondyloarthritis, polymyalgia rheumatica, myofascial pain syndromes and hypermobility syndrome.[89][10] Neurological diseases with an important pain component include multiple sclerosis, Parkinson's disease and peripheral neuropathy.[10][89] Other medical illnesses that should be ruled out are endocrine disease or metabolic disorder (hypothyroidism, hyperparathyroidism, acromegaly, vitamin D deficiency), gastro-intestinal disease (celiac and non-celiac gluten sensitivity), infectious diseases (Lyme disease, hepatitis C and immunodeficiency disease) and the early stages of a malignancy such as multiple myeloma, metastatic cancer and leukemia/lymphoma.[10][89] Other systemic, inflammatory, endocrine, rheumatic, infectious, and neurologic disorders may cause fibromyalgia-like symptoms, such as systemic lupus erythematosus, Sjögren syndrome, ankylosing spondylitis, Ehlers-Danlos syndromes, psoriatic-related polyenthesitis, a nerve compression syndrome (such as carpal tunnel syndrome), and myasthenia gravis.[52][88][90][91] In addition, several medications can also evoke pain (statins, aromatose inhibitors, biophosphonates, and opioids).[11]

The differential diagnosis is made during the evaluation on the basis of the person's medical history, physical examination, and laboratory investigations.[52][88][90][91] The patient's history can provide some hints to a fibromyalgia diagnosis. A family history of early chronic pain, a childhood history of pain, an emergence of broad pain following physical and/or psychosocial stress, a general hypersensitivity to touch, smell, noise, taste, hypervigilance, and various somatic symptoms (gastrointestinal, urology, gynecology, neurology), are all examples of these signals [10]

Extensive laboratory tests are usually unnecessary in the differential diagnosis of fibromyalgia.[11] Common tests that are conducted include complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate, C-reactive protein, and thyroid function test.[11]

Comorbidity[edit]

Fibromyalgia as a stand-alone diagnosis is uncommon, as most fibromyalgia patients often have other chronic overlapping pain problems or mental disorders.[10] Fibromyalgia is associated with mental health issues like anxiety,[92] posttraumatic stress disorder,[4][92] bipolar disorder,[92] and depression.[93][92] Patients with fibromyalgia are five times more likely to have major depression than the general population.[94]

Comorbid fibromyalgia has been reported to occur in 20–30% of individuals with rheumatic diseases.[93] It has been reported in people with noninflammatory musculoskeletal diseases.[93] Multiple sclerosis, post-polio syndrome, neuropathic pain, and Parkinson's disease are four neurological disorders that have been linked to pain or fibromyalgia.[93] The prevalence of fibromyalgia in gastrointestinal disease has been described mostly for celiac disease[93] and irritable bowel syndrome (IBS).[93][92] Fibromyalgia has also been linked with obesity.[95] Fibromyalgia and numerous chronic pain conditions frequently coexist.[93] These include chronic tension headaches,[92] myofascial pain syndrome,[92] and temporomandibular disorders.[92] Fibromyalgia is identified in 40–70 percent of persons with chronic fatigue syndrome.[96]

Management[edit]

As with many other medically unexplained syndromes, there is no universally accepted treatment or cure for fibromyalgia, and treatment typically consists of symptom management and improving patient quality of life.[13] A personalized, multidisciplinary approach to treatment that includes both non-pharmacologic and pharmacologic therapy and begins with effective patient education is most beneficial.[13] Developments in the understanding of the pathophysiology of the disorder have led to improvements in treatment, which include prescription medication, behavioral intervention, and exercise.

A number of associations have published guidelines for the diagnosis and management of fibromyalgia. The European League Against Rheumatism (EULAR; 2017)[14] recommends a multidisciplinary approach, allowing a quick diagnosis and patient education. The recommended initial management should be non-pharmacological, later pharmacological treatment can be added. The European League Against Rheumatism gave the strongest recommendation for aerobic and strengthening exercise. Weak recommendations were given to a number of treatments, based on their outcomes. Qigong, yoga, and tai chi were weakly recommended for improving sleep and quality of life. Mindfulness was weakly recommended for improving pain and quality of life. Acupuncture and hydrotherapy were weakly recommended for improving pain. A weak recommendation was also given to psychotherapy. It was more suitable for patients with mood disorders or unhelpful coping strategies. Chiropractic was strongly recommended against, due to safety concerns. Some medications were weakly recommended for severe pain (duloxetine, pregabalin, tramadol) or sleep disturbance (amitriptyline, cyclobenzaprine, pregabalin). Others were not recommended due to a lack of efficacy (nonsteroidal anti-inflammatory drugs, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors). Growth hormone, sodium oxybate, opioids and steroids were strongly recommended against due to lack of efficacy and side effects.

The guidelines published by the Association of the Scientific Medical Societies in Germany[97] inform patients that self-management strategies are an important component it managing the disease.[19] The Canadian Pain Society[98] also published guidelines for the diagnosis and management of fibromyalgia.

Exercise[edit]

Exercise is the only fibromyalgia treatment which has been given a strong recommendation by the European Alliance of Associations for Rheumatology (EULAR). There is strong evidence indicating that exercise improves fitness and sleep and may reduce pain, fatigue and quality of life for people with fibromyalgia.[99][18][100] Several studies have also found that exercise can improve cognitive functioning.[101][102][103] Exercise has an added benefit in that it does not cause any serious adverse effects.[100]

Exercise may diminish fibromyalgia symptoms through a number of hypothesized biological mechanisms.[44] Exercise may improve pain modulation[104][105] through serotoninergic pathways.[105] It may reduce pain by altering the hypothalamic-pituitary-adrenal axis and reducing cortisol levels.[106] It also has anti-inflammatory effects that may improve fibromyalgia symptoms.[107][108] Aerobic exercise can improve muscle metabolism and pain through mitochondrial pathways.[107]

When comparing different exercise programs, aerobic exercise is capable of modulating the autonomic nervous function of fibromyalgia patients, whereas resistance exercise does not show such effects.[109] Meditative exercise seems preferable for improving sleep, with no differences between resistance, flexibility and aquatic exercise in their favorable effects on fatigue.[110]

Despite its benefits, exercise is a challenge for patients with fibromyalgia, due to the chronic fatigue and pain they experience.[111] They perceive it as more effortful than healthy adults.[112] Exercise may intimidate them, in fear that they will be asked to do more than they are capable of.[113] They may also feel that those who recommend or deliver exercise interventions do not fully understand the possible negative impact of exercise on fatigue and pain.[113] This is especially true for non-personalized exercise programs.[113] Adherence is higher when the exercise program is recommended by doctors or supervised by nurses.[114] A recommended approach to a graded exercise program begins with small, frequent exercise periods and builds up from there.[115]

Aerobic[edit]

Aerobic exercise for fibromyalgia patients is the most investigated type of exercise.[100] It includes activities such as walking, jogging, spinning, cycling, dancing and exercising in water.[107][109] A 2017 cochrane summary concluded that aerobic exercise probably improves quality of life, slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness.[116] A 2019 meta-analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability.[109] This happens when patients exercise at least twice a week, for 45–60 minutes at about 60%-80% of the maximum heart rate.[109] Aerobic exercise also decreases anxiety and depression and improves the quality of life.[109]

Flexibility[edit]

Combinations of different exercises such as flexibility and aerobic training may improve stiffness.[117] However, the evidence is of low-quality.[117] It is not clear if flexibility training alone compared to aerobic training is effective at reducing symptoms or has any adverse effects.[118]

Resistance[edit]

In resistance exercise, participants apply a load to their body using weights, elastic band, body weight or other measures.

Two meta-analyses have shown that resistance training can reduce anxiety and depression[109][119] and one found that it improves quality of life.[109]

Along with endurance and coordination, consistent low-intensity with progressive workloads have been shown to decrease the perception of pain and decrease fatigue. Because physical exercise tends to improve the physical condition, the overall quality of life is also bettered.[120]

The dosage of resistance exercise for women with fibromyalgia was studied in a 2022 meta-analysis.[121] Effective dosages were found when exercising twice a week, for at least eight weeks. Symptom improvement was found for even low dosages such as 1–2 sets of 4–20 repetitions.[121] Most studies use moderate exercise intensity of 40% to 85% one-repetition maximum. This level of intensity was effective in reducing pain.[121] Some treatment regimes increase the intensity over time (from 40% to 80%), whereas others increase it when the participant is able to perform 12 repetitions.[121] High-intensity exercises may cause lower treatment adherence.

Meditative[edit]

A 2021 meta-analysis found that meditative exercise programs (tai chi, yoga, qigong) were superior to other forms of exercise (aerobic, flexibility, resistance) in improving sleep quality.[110] The positive effect of tai chi on sleep for people with diverse conditions has been documented in a second meta-analysis.[122] A third met-analysis from 2019 found that in addition to improving sleep, tai chi improves pain, fatigue, depression and quality of life, for patients with fibromyalgia.[123] These tai chi interventions frequently included 1-hour sessions practiced 1-3 times a week for 12 weeks. Meditative exercises, as a whole, may achieve desired outcomes through biological mechanisms such as antioxidation, anti-inflammation, reduction in sympathetic activity and modulation of glucocorticoid receptor sensitivity.[107]

Aquatic[edit]

Several reviews and meta-analyses suggest that aquatic training can improve symptoms and wellness in people with fibromyalgia.[124][125][126][127]

Other[edit]

Limited evidence suggests vibration training in combination with exercise may improve pain, fatigue, and stiffness.[128]

Medications[edit]

A few countries have published guidelines for the management and treatment of fibromyalgia. As of 2018, all of them emphasize that medications are not required, only optional. The German guidelines outlined parameters for drug therapy termination and recommended considering drug holidays after six months.[15]

Approved medications[edit]

Health Canada and the US Food and Drug Administration (FDA) have approved pregabalin[129] and duloxetine for the management of fibromyalgia. The FDA also approved milnacipran, but the European Medicines Agency refused marketing authority.[130]

Antidepressants[edit]

Antidepressants are one of the common drugs for fibromyalgia. A 2021 meta-analysis concluded that antidepressants can improve the quality of life for fibromyalgia patients in the medium-term.[16] As of 2018, the only tricyclic antidepressant (TCA) that has sufficient evidence is amitriptyline.[131][15]

For most people with fibromyalgia, the potential benefits of treatment with the serotonin and noradrenaline reuptake inhibitors (SNRI) duloxetine and milnacipran and the TCAs, such as amitriptyline, are outweighed by significant adverse effects (more adverse effects than benefits), however, a small number of people may experience relief from symptoms with these medications.[132][133][134] In addition, while amitriptyline has been used as a first line treatment, the quality of evidence to support this use and comparison between different medications is poor.[131][134] Very weak evidence indicates that a very small number of people may benefit from treatment with the tetracyclic antidepressant mirtazapine, however, for most, the potential benefits are not great and the risk of adverse effects and potential harm outweighs any potential for benefit.[135]

The length of time that antidepressant medications take to be effective at reducing symptoms can vary. Any potential benefits from the antidepressant amitriptyline may take up to three months to take effect and it may take between three and six months for duloxetine, milnacipran, and pregabalin to be effective at improving symptoms.[citation needed] Some medications have the potential to cause withdrawal symptoms when stopping so gradual discontinuation may be warranted particularly for antidepressants and pregabalin.[83]

There is tentative evidence that the benefits and harms of selective serotonin reuptake inhibitors (SSRIs) appear to be similar.[136] SSRIs may be used to treat depression in people diagnosed with fibromyalgia.[137]

Tentative evidence suggests that monoamine oxidase inhibitors (MAOIs) such as pirlindole and moclobemide are moderately effective for reducing pain.[138] Very low-quality evidence suggests pirlindole as more effective at treating pain than moclobemide.[138] Side effects of MAOIs may include nausea and vomiting.[138]

Central nervous system depressants[edit]

Central nervous system depressants include drug categories such as sedatives, tranquilizers, and hypnotics. A 2021 meta-analysis concluded that such drugs can improve the quality of life for fibromyalgia patients in the medium-term.[16]

Anti-seizure medication[edit]

The anti-convulsant medications gabapentin and pregabalin may be used to reduce pain.[7] There is tentative evidence that gabapentin may be of benefit for pain in about 18% of people with fibromyalgia.[7] It is not possible to predict who will benefit, and a short trial may be recommended to test the effectiveness of this type of medication. Approximately 6/10 people who take gabapentin to treat pain related to fibromyalgia experience unpleasant side effects such as dizziness, abnormal walking, or swelling from fluid accumulation.[139] Pregabalin demonstrates a benefit in about 9% of people.[140] Pregabalin reduced time off work by 0.2 days per week.[141]

Opioids[edit]

The use of opioids is controversial. As of 2015, no opioid is approved for use in this condition by the FDA.[142] A 2016 Cochrane review concluded that there is no good evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia.[143] The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 2014 stated that there was a lack of evidence for opioids for most people.[5] The Association of the Scientific Medical Societies in Germany in 2012 made no recommendation either for or against the use of weak opioids because of the limited amount of scientific research addressing their use in the treatment of FM. They strongly advise against using strong opioids.[97] The Canadian Pain Society in 2012 said that opioids, starting with a weak opioid like tramadol, can be tried but only for people with moderate to severe pain that is not well-controlled by non-opioid painkillers. They discourage the use of strong opioids and only recommend using them while they continue to provide improved pain and functioning. Healthcare providers should monitor people on opioids for ongoing effectiveness, side effects, and possible unwanted drug behaviors.[98]

A 2015 review found fair evidence to support tramadol use if other medications do not work.[142] A 2018 review found little evidence to support the combination of paracetamol (acetaminophen) and tramadol over a single medication.[144] Goldenberg et al suggest that tramadol works via its serotonin and norepinephrine reuptake inhibition, rather than via its action as a weak opioid receptor agonist.[145]

A large study of US people with fibromyalgia found that between 2005 and 2007 37.4% were prescribed short-acting opioids and 8.3% were prescribed long-acting opioids,[3] with around 10% of those prescribed short-acting opioids using tramadol;[146] and a 2011 Canadian study of 457 people with FM found 32% used opioids and two-thirds of those used strong opioids.[98]

Unapproved or unfounded[edit]

Sodium oxybate increases growth hormone production levels through increased slow-wave sleep patterns. However, this medication was not approved by the FDA for the indication for use in people with fibromyalgia due to the concern for abuse.[147]

The muscle relaxants cyclobenzaprine, carisoprodol with acetaminophen and caffeine, and tizanidine are sometimes used to treat fibromyalgia; however, as of 2015 they are not approved for this use in the United States.[148][149] The use of NSAIDs is not recommended as first line therapy.[150] Moreover, NSAIDs cannot be considered as useful in the management of fibromyalgia.[151]

Very low-quality evidence suggests quetiapine may be effective in fibromyalgia.[152]

No high-quality evidence exists that suggests synthetic THC (nabilone) helps with fibromyalgia.[153]

Others[edit]

Preliminary clinical data finds that low-dose naltrexone (LDN) may provide symptomatic improvement.[154]

A 1998 review concluded that intravenous Iloprost may be effective in reducing frequency and severity of attacks for people with fibromyalgia secondary to scleroderma.[155]

A 2013 review found moderate-level evidence on the usage of acupuncture with electrical stimulation for improvement of the overall well-being. Acupuncture alone will not have the same effects, but will enhance the influence of exercise and medication in pain and stiffness.[156]

Nutrition and dietary supplements[edit]

Although dietary supplements have been widely investigated in relation to fibromyalgia, most of the evidence, as of 2021, is of poor quality. It is therefore difficult to reach conclusive recommendations.[157]

A 2018 review on eight supplement studies concluded that Q10 coenzyme and vitamin D supplements can improve pain and quality of life for fibromyalgia patients.[18] A 2019 review showed that Q10 coenzyme has beneficial effects on fatigue in fibromyalgia patients, with most studies using doses of 300 mg per day for three months.[158] Q10 coenzyme is hypothesized to improve mitochondrial activity and decrease inflammation.[159]

A review article including four studies with 98 patients found that melatonin treatment has several positive effects on fibromyalgia patients, including the improvement of sleep quality, pain, and disease impact. No major adverse events were reported.[160]

Low-quality evidence found an improvement in symptoms with a gluten-free diet for people with a combination of both fibromyalgia and lymphocytotic enteritis.[161][162][163] Low-quality evidence also exists for the benefits of a vegetarian or vegan diet.[164]

Psychotherapy[edit]

Due to the uncertainty about the pathogenesis of FM, current treatment approaches focus on management of symptoms to improve quality of life,[165] using integrated pharmacological and non-pharmacological approaches.[4] There is no single intervention shown to be effective for all patients.[166] In a 2020 Cochrane review cognitive behavioral therapy (CBT) was found to have a small but beneficial effect for reducing pain and distress but adverse events were not well evaluated.[167]

Non-pharmacological components include CBT, exercise, and psychoeducation (specifically, sleep hygiene).[168][169][166][170] CBT and related psychological and behavioural therapies have a small to moderate effect in reducing symptoms of fibromyalgia.[171][169] Effect sizes tend to be small when CBT is used as a stand-alone treatment for FM patients, but these improve significantly when CBT is part of a wider multidisciplinary treatment program.[169]

A 2010 systematic review of 14 studies reported that CBT improves self-efficacy or coping with pain and reduces the number of physician visits at post-treatment, but has no significant effect on pain, fatigue, sleep, or health-related quality of life at post-treatment or follow-up. Depressed mood was also improved but this could not be distinguished from some risks of bias.[172]

Manual Therapy[edit]

A survey conducted on 310 patients from the Mayo Clinic found that 50% reported using massage therapy and 39% chiropractic treatment.[173]

A 2021 meta-analysis concluded that massage and myofascial release diminish pain in the medium-term.[16]

As of 2015, there was no good evidence for the benefit of other mind-body therapies.[174]

Transcutaneous electrical nerve stimulation (TENS)[edit]

Transcutaneous electrical nerve stimulation (TENS) is the delivery of pulsed electrical currents to the skin to stimulate peripheral nerves. TENS is widely used to treat pain and is considered to be a low-cost, safe, and self-administered treatment.[175] As such, it is commonly recommended by clinicians to people suffering from pain.[176] On 2019, an overview of eight Cochrane reviews was conducted, covering 51 TENS-related randomized controlled trials.[176] The review concluded that the quality of the available evidence was insufficient to make any recommendations.[176] In 2020, a randomized controlled trial documented a positive therapeutic effect of TENS on movement-evoked pain and fatigue.[177] A 2021 meta-analysis concluded that transcutaneous electrical nerve stimulation may diminish pain in the short-term, but there was uncertainty about the relevance of the results.[16]

Preliminary findings suggest that electrically stimulating the vagus nerve through an implanted device can potentially reduce fibromyalgia symptoms.[66] However, there may be adverse reactions to the procedure.[66]

Magnetic therapy[edit]

A 2021 meta-analysis of multiple intervention types concluded that magnetic field therapy and transcranial magnetic stimulation may diminish pain in the short-term, but conveyed an uncertainty about the relevance of the result.[16] Two 2022 meta-analyses focusing on transcranial magnetic stimulation found positive effects on fibromyalgia. Repetitive transcranial magnetic stimulation improved pain in the short-term[178][179] and quality of life after 5–12 weeks.[178][179] Repetitive transcranial magnetic stimulation did not improve anxiety, depression, and fatigue.[179] Transcranial magnetic stimulation to the left dorsolateral prefrontal cortex was also ineffective.[178]

Hyperbaric oxygen therapy[edit]

Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain. However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials.[107] In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it.[107]

Prognosis[edit]

Although in itself fibromyalgia is neither degenerative nor fatal, the chronic pain of fibromyalgia is pervasive and persistent. Most people with fibromyalgia report that their symptoms do not improve over time. However, most patients learn to adapt to the symptoms over time. The German guidelines for patients explain that:

  1. The symptoms of fibromyalgia are persistent in nearly all patients.
  2. Total relief of symptoms is seldom achieved.
  3. The symptoms do not lead to disablement and do not shorten life expectancy.[19]

An 11-year follow-up study on 1555 patients found that most remained with high levels of self-reported symptoms and distress.[non-primary source needed][180] However, there was a great deal of patient heterogeneity accounting for almost half of the variance. At the final observation, 10% of the patients showed substantial improvement minimal symptoms. An additional 15% had moderate improvement. This state, though, may be transient, given the fluctuations in symptom severity.[non-primary source needed][180]

A study of 97 adolescents diagnosed with fibromyalgia followed them for eight years.[non-primary source needed][181] After eight years, the majority of youth still experienced pain and disability in physical, social, and psychological areas. At the last follow-up, all participants reported experiencing one or more fibromyalgia symptoms such pain, fatigue, and/or sleep problems, with 58% matching the complete ACR 2010 criteria for fibromyalgia. Based on the WPI and SS score cut-points, the remaining 42% exhibited subclinical symptoms. Pain and emotional symptom trajectories, on the other hand, displayed a variety of longitudinal patterns. The study concluded that while most patient's fibromyalgia symptoms endure, the severity of their pain tends to reduce over time.[181]

Baseline depressive symptoms in adolescents appear to predict worse pain at follow-up periods.[unreliable medical source?][181][182]

Epidemiology[edit]

Fibromyalgia is estimated to affect 2–4% of the population.[15]

Females are affected about twice as often as males based on criteria as of 2014.[4]

History[edit]

Chronic widespread pain had already been described in the literature in the 19th century but the term fibromyalgia was not used until 1976 when Dr P.K. Hench used it to describe these symptoms.[83] Many names, including "muscular rheumatism", "fibrositis", "psychogenic rheumatism", and "neurasthenia" were applied historically to symptoms resembling those of fibromyalgia.[183] The term fibromyalgia was coined by researcher Mohammed Yunus as a synonym for fibrositis and was first used in a scientific publication in 1981.[184] Fibromyalgia is from the Latin fibra (fiber)[185] and the Greek words myo (muscle)[186] and algos (pain).[187]

Historical perspectives on the development of the fibromyalgia concept note the "central importance" of a 1977 paper by Smythe and Moldofsky on fibrositis.[188][189] The first clinical, controlled study of the characteristics of fibromyalgia syndrome was published in 1981,[190] providing support for symptom associations. In 1984, an interconnection between fibromyalgia syndrome and other similar conditions was proposed,[191] and in 1986, trials of the first proposed medications for fibromyalgia were published.[191]

A 1987 article in the Journal of the American Medical Association used the term "fibromyalgia syndrome" while saying it was a "controversial condition".[192] The American College of Rheumatology (ACR) published its first classification criteria for fibromyalgia in 1990.[193] Later revisions were made in 2010,[84] 2016,[8] and 2019.[11]

Society and culture[edit]

Economics[edit]

People with fibromyalgia generally have higher healthcare costs and utilization rates. A study of almost 20,000 Humana members enrolled in Medicare Advantage and commercial plans compared costs and medical utilizations and found that people with fibromyalgia used twice as much pain-related medication as those without fibromyalgia. Furthermore, the use of medications and medical necessities increased markedly across many measures once a diagnosis was made.[194]

Controversies[edit]

Fibromyalgia was defined relatively recently. In the past, it was a disputed diagnosis. Frederick Wolfe, lead author of the 1990 paper that first defined the diagnostic guidelines for fibromyalgia, stated in 2008 that he believed it "clearly" not to be a disease but instead a physical response to depression and stress.[195] In 2013 Wolfe added that its causes "are controversial in a sense" and "there are many factors that produce these symptoms – some are psychological and some are physical and it does exist on a continuum".[196] Some members of the medical community did not consider fibromyalgia a disease because of a lack of abnormalities on physical examination and the absence of objective diagnostic tests.[188][197]

In the past, some psychiatrists have viewed fibromyalgia as a type of affective disorder, or a somatic symptom disorder. These controversies do not engage healthcare specialists alone; some patients object to fibromyalgia being described in purely somatic terms.

As of 2022, neurologists and pain specialists tend to view fibromyalgia as a pathology due to dysfunction of muscles and connective tissue as well as functional abnormalities in the central nervous system. Rheumatologists define the syndrome in the context of "central sensitization" – heightened brain response to normal stimuli in the absence of disorders of the muscles, joints, or connective tissues. Because of this symptomatic overlap, some researchers have proposed that fibromyalgia and other analogous syndromes be classified together as central sensitivity syndromes.[198][12]

Notes[edit]

  1. ^ Shoulder girdle (left & right), upper arm (left & right), lower arm (left & right), hip/buttock/trochanter (left & right), upper leg (left & right), lower leg (left & right), jaw (left & right), chest, abdomen, back (upper & lower), and neck.[84]: 607 
  2. ^ Somatic symptoms include, but are not limited to: muscle pain, irritable bowel syndrome, fatigue or tiredness, problems thinking or remembering, muscle weakness, headache, pain or cramps in the abdomen, numbness or tingling, dizziness, insomnia, depression, constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud's phenomenon, hives or welts, ringing in the ears, vomiting, heartburn, oral ulcers, loss of or changes in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy bruising, hair loss, frequent or painful urination, and bladder spasms.[84]: 607 

References[edit]

  1. ^ "fibromyalgia". Collins Dictionaries. Archived from the original on 4 October 2015. Retrieved 16 March 2016.
  2. ^ "Neurology Now: Fibromyalgia: Is Fibromyalgia Real? | American Academy of Neurology". tools.aan.com. October 2009. Retrieved 1 June 2018.[permanent dead link]
  3. ^ a b c Ngian GS, Guymer EK, Littlejohn GO (February 2011). "The use of opioids in fibromyalgia". International Journal of Rheumatic Diseases. 14 (1): 6–11. doi:10.1111/j.1756-185X.2010.01567.x. PMID 21303476. S2CID 29000267.
  4. ^ a b c d e f g h i j k l m n Clauw DJ (April 2014). "Fibromyalgia: a clinical review". JAMA. 311 (15): 1547–1555. doi:10.1001/jama.2014.3266. PMID 24737367. S2CID 43693607.
  5. ^ a b c d e f g "Questions and Answers about Fibromyalgia". NIAMS. July 2014. Archived from the original on 15 March 2016. Retrieved 15 March 2016.
  6. ^ Ferri FF (2010). "Chapter F". Ferri's differential diagnosis : a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia, PA: Elsevier/Mosby. ISBN 978-0323076999.
  7. ^ a b c Cooper TE, Derry S, Wiffen PJ, Moore RA (January 2017). "Gabapentin for fibromyalgia pain in adults". The Cochrane Database of Systematic Reviews. 1: CD012188. doi:10.1002/14651858.CD012188.pub2. PMC 6465053. PMID 28045473.
  8. ^ a b c d e f g Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. (December 2016). "2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria". Seminars in Arthritis and Rheumatism. 46 (3): 319–329. doi:10.1016/j.semarthrit.2016.08.012. PMID 27916278.
  9. ^ a b Wu YL, Chang LY, Lee HC, Fang SC, Tsai PS (May 2017). "Sleep disturbances in fibromyalgia: A meta-analysis of case-control studies". Journal of Psychosomatic Research. 96: 89–97. doi:10.1016/j.jpsychores.2017.03.011. PMID 28545798.
  10. ^ a b c d e f g Häuser W, Sarzi-Puttini P, Fitzcharles MA (2019). "Fibromyalgia syndrome: under-, over- and misdiagnosis". Clinical and Experimental Rheumatology. 37 (1): 90–97. PMID 30747096.
  11. ^ a b c d e f g h i j k l m n o p q r s t u Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, et al. (June 2019). "AAPT Diagnostic Criteria for Fibromyalgia". The Journal of Pain. 20 (6): 611–628. doi:10.1016/j.jpain.2018.10.008. PMID 30453109. S2CID 53872511.
  12. ^ a b c Mezhov V, Guymer E, Littlejohn G (December 2021). "Central sensitivity and fibromyalgia". Internal Medicine Journal. 51 (12): 1990–1998. doi:10.1111/imj.15430. PMID 34139045. S2CID 235471910.
  13. ^ a b c Prabhakar A, Kaiser JM, Novitch MB, Cornett EM, Urman RD, Kaye AD (March 2019). "The Role of Complementary and Alternative Medicine Treatments in Fibromyalgia: a Comprehensive Review". Current Rheumatology Reports. 21 (5): 14. doi:10.1007/s11926-019-0814-0. PMID 30830504. S2CID 73482737.
  14. ^ a b c d e Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. (December 2017). "EULAR recommendations for management of fibromyalgia" (PDF). Annals of the Rheumatic Diseases. 76 (12): e54. doi:10.1136/annrheumdis-2017-211587. PMID 28476880. S2CID 26251476.
  15. ^ a b c d e f Häuser W, Fitzcharles MA (March 2018). "Facts and myths pertaining to fibromyalgia". Dialogues in Clinical Neuroscience. 20 (1): 53–62. doi:10.31887/dcns.2018.20.1/whauser. PMC 6016048. PMID 29946212.
  16. ^ a b c d e f Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC (January 2021). "Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis". JAMA Internal Medicine. 181 (1): 104–112. doi:10.1001/jamainternmed.2020.5651. PMC 7589080. PMID 33104162.
  17. ^ Kia S, Choy E (May 2017). "Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology". Biomedicines. 5 (2): 20. doi:10.3390/biomedicines5020020. PMC 5489806. PMID 28536363.
  18. ^ a b c Ibáñez-Vera AJ, Alvero-Cruz JR, García-Romero JC (2018). "Therapeutic physical exercise and supplements to treat fibromyalgia". Apunts. Medicina de l'Esport. 53 (197): 33–41. doi:10.1016/j.apunts.2017.07.001.
  19. ^ a b c Fitzcharles MA, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, Häuser W (2013). "Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines". Evidence-Based Complementary and Alternative Medicine. 2013: 528952. doi:10.1155/2013/528952. PMC 3860136. PMID 24379886.
  20. ^ a b c d e f g Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W (May 2021). "Nociplastic pain: towards an understanding of prevalent pain conditions". Lancet. 397 (10289): 2098–2110. doi:10.1016/s0140-6736(21)00392-5. PMID 34062144. S2CID 235245552.
  21. ^ Bergmann U (2012). Neurobiological foundations for EMDR practice. New York: Springer Pub. Co. p. 165. ISBN 978-0826109385.
  22. ^ a b Clauw DJ, Arnold LM, McCarberg BH (September 2011). "The science of fibromyalgia". Mayo Clinic Proceedings. 86 (9): 907–11. doi:10.4065/mcp.2011.0206. PMC 3258006. PMID 21878603.
  23. ^ "ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Retrieved 9 April 2022.
  24. ^ Besiroglu MD, Dursun MD (July 2019). "The association between fibromyalgia and female sexual dysfunction: a systematic review and meta-analysis of observational studies". International Journal of Impotence Research. 31 (4): 288–297. doi:10.1038/s41443-018-0098-3. PMID 30467351. S2CID 53717513.
  25. ^ Zdebik N, Zdebik A, Bogusławska J, Przeździecka-Dołyk J, Turno-Kręcicka A (January 2021). "Fibromyalgia syndrome and the eye-A review". Survey of Ophthalmology. 66 (1): 132–137. doi:10.1016/j.survophthal.2020.05.006. PMID 32512032. S2CID 219548664.
  26. ^ "Fibromyalgia – Symptoms". nhs.uk. 20 October 2017. Retrieved 21 October 2020.
  27. ^ Meeus M, Nijs J (April 2007). "Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome". Clinical Rheumatology. 26 (4): 465–473. doi:10.1007/s10067-006-0433-9. PMC 1820749. PMID 17115100.
  28. ^ Wolfe F, Rasker JJ, Ten Klooster P, Häuser W (December 2021). "Subjective Cognitive Dysfunction in Patients With and Without Fibromyalgia: Prevalence, Predictors, Correlates, and Consequences". Cureus. 13 (12): e20351. doi:10.7759/cureus.20351. PMC 8752385. PMID 35036191.
  29. ^ a b c d Buskila D, Cohen H (October 2007). "Comorbidity of fibromyalgia and psychiatric disorders". Current Pain and Headache Reports. 11 (5): 333–338. doi:10.1007/s11916-007-0214-4. PMID 17894922. S2CID 28038437.
  30. ^ Mercado F, Ferrera D, Fernandes-Magalhaes R, Peláez I, Barjola P (March 2022). "Altered Subprocesses of Working Memory in Patients with Fibromyalgia: An Event-Related Potential Study Using N-Back Task". Pain Medicine. 23 (3): 475–487. doi:10.1093/pm/pnab190. PMID 34145889.
  31. ^ a b c Bell T, Trost Z, Buelow MT, Clay O, Younger J, Moore D, Crowe M (September 2018). "Meta-analysis of cognitive performance in fibromyalgia". Journal of Clinical and Experimental Neuropsychology. 40 (7): 698–714. doi:10.1080/13803395.2017.1422699. PMC 6151134. PMID 29388512.
  32. ^ Berwick RJ, Siew S, Andersson DA, Marshall A, Goebel A (May 2021). "A Systematic Review Into the Influence of Temperature on Fibromyalgia Pain: Meteorological Studies and Quantitative Sensory Testing". The Journal of Pain. 22 (5): 473–486. doi:10.1016/j.jpain.2020.12.005. PMID 33421589. S2CID 231437516.
  33. ^ Staud R, Godfrey MM, Robinson ME (August 2021). "Fibromyalgia Patients Are Not Only Hypersensitive to Painful Stimuli But Also to Acoustic Stimuli". The Journal of Pain. 22 (8): 914–925. doi:10.1016/j.jpain.2021.02.009. PMID 33636370. S2CID 232066286.
  34. ^ a b c d e D'Agnelli S, Arendt-Nielsen L, Gerra MC, Zatorri K, Boggiani L, Baciarello M, Bignami E (January 2019). "Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers". Molecular Pain. 15: 1744806918819944. doi:10.1177/1744806918819944. PMC 6322092. PMID 30486733.
  35. ^ a b c Ablin JN, Buskila D (February 2015). "Update on the genetics of the fibromyalgia syndrome". Best Practice & Research. Clinical Rheumatology. 29 (1): 20–28. doi:10.1016/j.berh.2015.04.018. PMID 26266996.
  36. ^ Lee YH, Choi SJ, Ji JD, Song GG (February 2012). "Candidate gene studies of fibromyalgia: a systematic review and meta-analysis". Rheumatology International. 32 (2): 417–426. doi:10.1007/s00296-010-1678-9. PMID 21120487. S2CID 6239018.
  37. ^ Dutta D, Brummett CM, Moser SE, Fritsche LG, Tsodikov A, Lee S, et al. (May 2020). "Heritability of the Fibromyalgia Phenotype Varies by Age". Arthritis & Rheumatology. 72 (5): 815–823. doi:10.1002/art.41171. PMC 8372844. PMID 31736264.
  38. ^ Maletic V, Raison CL (June 2009). "Neurobiology of depression, fibromyalgia and neuropathic pain". Frontiers in Bioscience. 14 (14): 5291–338. doi:10.2741/3598. PMID 19482616.
  39. ^ a b c Martins DF, Viseux FJ, Salm DC, Ribeiro AC, da Silva HK, Seim LA, et al. (December 2021). "The role of the vagus nerve in fibromyalgia syndrome". Neuroscience and Biobehavioral Reviews. 131: 1136–1149. doi:10.1016/j.neubiorev.2021.10.021. PMID 34710514. S2CID 239772451.
  40. ^ a b Kaleycheva N, Cullen AE, Evans R, Harris T, Nicholson T, Chalder T (January 2021). "The role of lifetime stressors in adult fibromyalgia: systematic review and meta-analysis of case-control studies". Psychological Medicine. 51 (2): 177–193. doi:10.1017/S0033291720004547. PMID 33602373. S2CID 231955641.
  41. ^ Schmidt-Wilcke T, Clauw DJ (July 2011). "Fibromyalgia: from pathophysiology to therapy". Nature Reviews. Rheumatology. 7 (9): 518–527. doi:10.1038/nrrheum.2011.98. PMID 21769128. S2CID 20678671.
  42. ^ Casale, Roberto; Sarzi-Puttini, Piercarlo; Botto, Rossana; Alciati, Alessandra; Batticciotto, Alberto; Marotto, Daniela; Torta, Riccardo (January 2019). "Fibromyalgia and the concept of resilience". Clinical and Experimental Rheumatology. 37 Suppl 116 (1): 105–113. ISSN 0392-856X. PMID 30747098.
  43. ^ [unreliable medical source?] Grisart J, Scaillet N, Michaux M, Masquelier E, Fantini C, Luminet O (July 2020). "Determinants of representational and behavioral hyperactivity in patients with fibromyalgia syndrome". Journal of Health Psychology. 25 (8): 1128–1137. doi:10.1177/1359105317751616. PMID 29310454. S2CID 23264749.
  44. ^ a b [unreliable medical source?] Masquelier E, D'haeyere J (October 2021). "Physical activity in the treatment of fibromyalgia". Joint Bone Spine. 88 (5): 105202. doi:10.1016/j.jbspin.2021.105202. PMID 33962033.
  45. ^ Schweinhardt P, Sauro KM, Bushnell MC (October 2008). "Fibromyalgia: a disorder of the brain?". The Neuroscientist. 14 (5): 415–21. doi:10.1177/1073858407312521. PMID 18270311. S2CID 16654849.
  46. ^ Conversano, Ciro; Marchi, Laura; Ciacchini, Rebecca; Carmassi, Claudia; Contena, Bastianina; Bazzichi, Laura Maria; Gemignani, Angelo (28 September 2018). "Personality Traits in Fibromyalgia (FM): Does FM Personality Exists? A Systematic Review". Clinical Practice & Epidemiology in Mental Health. 14 (1): 223–232. doi:10.2174/1745017901814010223. ISSN 1745-0179. PMC 6166394. PMID 30294356.
  47. ^ Sommer C, Häuser W, Burgmer M, Engelhardt R, Gerhold K, Petzke F, et al. (June 2012). "[Etiology and pathophysiology of fibromyalgia syndrome]". Schmerz. 26 (3): 259–67. doi:10.1007/s00482-012-1174-0. PMID 22760458. S2CID 33277191.
  48. ^ Moldofsky H, Scarisbrick P, England R, Smythe H (1975). "Musculosketal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects". Psychosomatic Medicine. 37 (4): 341–351. doi:10.1097/00006842-197507000-00008. PMID 169541. S2CID 34100321.
  49. ^ Moldofsky H, Scarisbrick P (January–February 1976). "Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation". Psychosomatic Medicine. 38 (1): 35–44. doi:10.1097/00006842-197601000-00006. PMID 176677. S2CID 27588469.
  50. ^ [unreliable medical source?] Mork PJ, Nilsen TI (January 2012). "Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway". Arthritis and Rheumatism. 64 (1): 281–84. doi:10.1002/art.33346. PMID 22081440. S2CID 13274649.
  51. ^ Spaeth M, Rizzi M, Sarzi-Puttini P (April 2011). "Fibromyalgia and sleep". Best Practice & Research. Clinical Rheumatology. 25 (2): 227–239. doi:10.1016/j.berh.2011.03.004. PMID 22094198.
  52. ^ a b c Rossi A, Di Lollo AC, Guzzo MP, Giacomelli C, Atzeni F, Bazzichi L, Di Franco M (2015). "Fibromyalgia and nutrition: what news?". Clinical and Experimental Rheumatology. 33 (1 Suppl 88): S117–25. PMID 25786053.
  53. ^ San Mauro Martín I, Garicano Vilar E, Collado Yurrutia L, Ciudad Cabañas MJ (December 2014). "[Is gluten the great etiopathogenic agent of disease in the XXI century?]". Nutricion Hospitalaria. 30 (6): 1203–10. doi:10.3305/nh.2014.30.6.7866. PMID 25433099.
  54. ^ a b Tan AC, Jaaniste T, Champion D (5 May 2019). "Chronic Widespread Pain and Fibromyalgia Syndrome: Life-Course Risk Markers in Young People". Pain Research & Management. 2019: 6584753. doi:10.1155/2019/6584753. PMC 6525804. PMID 31191788.
  55. ^ de Tommaso M, Vecchio E, Nolano M (March 2022). "The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence". Neurological Sciences. 43 (3): 1667–1684. doi:10.1007/s10072-021-05806-x. PMID 35028777. S2CID 245909381.
  56. ^ den Boer C, Dries L, Terluin B, van der Wouden JC, Blankenstein AH, van Wilgen CP, et al. (February 2019). "Central sensitization in chronic pain and medically unexplained symptom research: A systematic review of definitions, operationalizations and measurement instruments". Journal of Psychosomatic Research. 117: 32–40. doi:10.1016/j.jpsychores.2018.12.010. PMID 30665594. S2CID 58565532.
  57. ^ a b c d Bradley LA (December 2009). "Pathophysiology of fibromyalgia". The American Journal of Medicine. 122 (12 Suppl): S22–30. doi:10.1016/j.amjmed.2009.09.008. PMC 2821819. PMID 19962493.
  58. ^ a b Solitar BM (1 January 2010). "Fibromyalgia: knowns, unknowns, and current treatment". Bulletin of the NYU Hospital for Joint Diseases. 68 (3): 157–61. PMID 20969544.
  59. ^ a b Martínez-Lavín M (December 2018). "Fibromyalgia and small fiber neuropathy: the plot thickens!". Clinical Rheumatology. 37 (12): 3167–3171. doi:10.1007/s10067-018-4300-2. PMID 30238382. S2CID 52306843.
  60. ^ Martínez-Lavín M (February 2021). "Dorsal root ganglia: fibromyalgia pain factory?". Clinical Rheumatology. 40 (2): 783–787. doi:10.1007/s10067-020-05528-z. PMC 7787228. PMID 33409721.
  61. ^ Reyes Del Paso GA, de la Coba P (29 October 2020). Malik RA (ed.). "Reduced activity, reactivity and functionality of the sympathetic nervous system in fibromyalgia: An electrodermal study". PLOS ONE. 15 (10): e0241154. Bibcode:2020PLoSO..1541154R. doi:10.1371/journal.pone.0241154. PMC 7595305. PMID 33119628.
  62. ^ Papadopoulou M, Papapostolou A, Bakola E, Masdrakis VG, Moschovos C, Chroni E, et al. (September 2021). "Neurophysiological and ultrasonographic comparative study of autonomous nervous system in patients suffering from fibromyalgia and generalized anxiety disorder". Neurological Sciences. 43 (4): 2813–2821. doi:10.1007/s10072-021-05606-3. PMID 34557968. S2CID 237611157.
  63. ^ a b Martinez-Lavin M, Holman AJ (2021). "Heart rate variability analysis in rheumatology: past, present… and future?". Clinical and Experimental Rheumatology. 39 (5): 927–930. PMID 34464245.
  64. ^ Figueroa A, Kingsley JD, McMillan V, Panton LB (January 2008). "Resistance exercise training improves heart rate variability in women with fibromyalgia". Clinical Physiology and Functional Imaging. 28 (1): 49–54. doi:10.1111/j.1475-097X.2007.00776.x. PMID 18005081. S2CID 40592827.
  65. ^ Park HY, Jung WS, Kim J, Hwang H, Lim K (March 2020). "Twelve Weeks of Aerobic Exercise at the Lactate Threshold Improves Autonomic Nervous System Function, Body Composition, and Aerobic Performance in Women with Obesity". Journal of Obesity & Metabolic Syndrome. 29 (1): 67–75. doi:10.7570/jomes19063. PMC 7118007. PMID 32045515.
  66. ^ a b c Lange G, Janal MN, Maniker A, Fitzgibbons J, Fobler M, Cook D, Natelson BH (September 2011). "Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial". Pain Medicine. 12 (9): 1406–1413. doi:10.1111/j.1526-4637.2011.01203.x. PMC 3173600. PMID 21812908.
  67. ^ a b c d Singh, Lovedeep; Kaur, Anudeep; Bhatti, Manpreet S.; Bhatti, Rajbir (July 2019). "Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co-morbidities". Neurochemical Research. 44 (7): 1517–1532. doi:10.1007/s11064-019-02805-5. ISSN 0364-3190. PMID 31004261. S2CID 123945497.
  68. ^ a b c Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, Blonna D (1 January 2012). "Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment". Pain Research and Treatment. 2012: 426130. doi:10.1155/2012/426130. PMC 3503476. PMID 23213512.
  69. ^ Dadabhoy D, Clauw DJ (July 2006). "Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment". Nature Clinical Practice. Rheumatology. 2 (7): 364–372. doi:10.1038/ncprheum0221. PMID 16932722. S2CID 10643705.
  70. ^ Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU (December 2009). "Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise". Current Neuropharmacology. 7 (4): 331–336. doi:10.2174/157015909790031201. PMC 2811866. PMID 20514212.
  71. ^ Lin C, Lee SH, Weng HH (1 January 2016). "Gray Matter Atrophy within the Default Mode Network of Fibromyalgia: A Meta-Analysis of Voxel-Based Morphometry Studies". BioMed Research International. 2016: 7296125. doi:10.1155/2016/7296125. PMC 5220433. PMID 28105430.
  72. ^ Napadow V, Harris RE (1 January 2014). "What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of 'centralized' pain?". Arthritis Research & Therapy. 16 (5): 425. doi:10.1186/s13075-014-0425-0. PMC 4289059. PMID 25606591.
  73. ^ Coskun Benlidayi I (May 2019). "Role of inflammation in the pathogenesis and treatment of fibromyalgia". Rheumatology International. 39 (5): 781–791. doi:10.1007/s00296-019-04251-6. PMID 30756137. S2CID 131775636.
  74. ^ a b c Uçeyler N, Häuser W, Sommer C (October 2011). "Systematic review with meta-analysis: cytokines in fibromyalgia syndrome". BMC Musculoskeletal Disorders. 12: 245. doi:10.1186/1471-2474-12-245. PMC 3234198. PMID 22034969.
  75. ^ a b c Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y (October 2014). "Fibromyalgia and cytokines". Immunology Letters. 161 (2): 200–03. doi:10.1016/j.imlet.2014.01.009. PMID 24462815.
  76. ^ Dell'Osso L, Bazzichi L, Baroni S, Falaschi V, Conversano C, Carmassi C, Marazziti D (1 January 2015). "The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome". Clinical and Experimental Rheumatology. 33 (1 Suppl 88): S109–16. PMID 25786052.
  77. ^ a b Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, Sarzi-Puttini P (2020). "One year in review 2020: fibromyalgia". Clin Exp Rheumatol. 38 (1): 3–8. PMID 32116216.
  78. ^ Littlejohn G (November 2015). "Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome". Nature Reviews. Rheumatology. 11 (11): 639–48. doi:10.1038/nrrheum.2015.100. PMID 26241184. S2CID 4368913.
  79. ^ a b c d [unreliable medical source?] Minerbi A, Gonzalez E, Brereton NJ, Anjarkouchian A, Dewar K, Fitzcharles MA, et al. (November 2019). "Altered microbiome composition in individuals with fibromyalgia". Pain. 160 (11): 2589–2602. doi:10.1097/j.pain.0000000000001640. PMID 31219947. S2CID 195187754.
  80. ^ Erdrich S, Hawrelak JA, Myers SP, Harnett JE (March 2020). "Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review". BMC Musculoskeletal Disorders. 21 (1): 181. doi:10.1186/s12891-020-03201-9. PMC 7083062. PMID 32192466.
  81. ^ Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín JL, van Liempd S, et al. (August 2019). "Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia". EBioMedicine. 46: 499–511. doi:10.1016/j.ebiom.2019.07.031. PMC 6710987. PMID 31327695.
  82. ^ Wolfe F (August 2003). "Stop using the American College of Rheumatology criteria in the clinic". The Journal of Rheumatology. 30 (8): 1671–72. PMID 12913920. Archived from the original on 14 October 2011.
  83. ^ a b c Häuser W, Eich W, Herrmann M, Nutzinger DO, Schiltenwolf M, Henningsen P (June 2009). "Fibromyalgia syndrome: classification, diagnosis, and treatment". Deutsches Ärzteblatt International. 106 (23): 383–391. doi:10.3238/arztebl.2009.0383. PMC 2712241. PMID 19623319.
  84. ^ a b c d e f Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. (May 2010). "The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity". Arthritis Care & Research. 62 (5): 600–10. doi:10.1002/acr.20140. hdl:2027.42/75772. PMID 20461783. S2CID 17154205.
  85. ^ a b Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (June 2015). "Fibromyalgia diagnosis: a review of the past, present and future". Expert Review of Neurotherapeutics. 15 (6): 667–79. doi:10.1586/14737175.2015.1046841. PMID 26035624. S2CID 2412984.
  86. ^ Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL (1 January 2009). "The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties". Arthritis Research & Therapy. 11 (4): R120. doi:10.1186/ar2783. PMC 2745803. PMID 19664287.
  87. ^ Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A (February 1994). "Development and validation of a Multiple Ability Self-Report Questionnaire". Journal of Clinical and Experimental Neuropsychology. 16 (1): 93–104. doi:10.1080/01688639408402620. PMID 8150893.
  88. ^ a b c Goldenberg DL (December 2009). "Diagnosis and differential diagnosis of fibromyalgia". The American Journal of Medicine (Review). 122 (12 Suppl): S14–21. doi:10.1016/j.amjmed.2009.09.007. PMID 19962492.
  89. ^ a b c Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA (May 2017). "Diagnostic confounders of chronic widespread pain: not always fibromyalgia". Pain Reports. 2 (3): e598. doi:10.1097/PR9.0000000000000598. PMC 5741304. PMID 29392213.
  90. ^ a b Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG (January 2018). "The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia" (PDF). Rheumatology (Review). 57 (1): 32–40. doi:10.1093/rheumatology/kex079. PMID 28387854. S2CID 205309871.
  91. ^ a b Palazzi C, D'Amico E, D'Angelo S, Gilio M, Olivieri I (January 2016). "Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis". World Journal of Gastroenterology (Review). 22 (4): 1405–10. doi:10.3748/wjg.v22.i4.1405. PMC 4721975. PMID 26819509.
  92. ^ a b c d e f g h Kleykamp, Bethea A.; Ferguson, McKenzie C.; McNicol, Ewan; Bixho, Ida; Arnold, Lesley M.; Edwards, Robert R.; Fillingim, Roger; Grol-Prokopczyk, Hanna; Turk, Dennis C.; Dworkin, Robert H. (February 2021). "The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review". Seminars in Arthritis and Rheumatism. 51 (1): 166–174. doi:10.1016/j.semarthrit.2020.10.006. PMID 33383293. S2CID 229948862.
  93. ^ a b c d e f g Fitzcharles MA, Perrot S, Häuser W (October 2018). "Comorbid fibromyalgia: A qualitative review of prevalence and importance". European Journal of Pain. 22 (9): 1565–1576. doi:10.1002/ejp.1252. PMID 29802812. S2CID 44068037.
  94. ^ Løge-Hagen, J.S.; Sæle, A.; Juhl, C.; Bech, P.; Stenager, E.; Mellentin, Ai (February 2019). "Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis". Journal of Affective Disorders. 245: 1098–1105. doi:10.1016/j.jad.2018.12.001. PMID 30699852. S2CID 73411416.
  95. ^ D'Onghia, Martina; Ciaffi, Jacopo; Lisi, Lucia; Mancarella, Luana; Ricci, Susanna; Stefanelli, Nicola; Meliconi, Riccardo; Ursini, Francesco (April 2021). "Fibromyalgia and obesity: A comprehensive systematic review and meta-analysis". Seminars in Arthritis and Rheumatism. 51 (2): 409–424. doi:10.1016/j.semarthrit.2021.02.007. PMID 33676126. S2CID 232136088.
  96. ^ Anderson G, Maes M (December 2020). "Mitochondria and immunity in chronic fatigue syndrome". Progress in Neuro-psychopharmacology & Biological Psychiatry. 103: 109976. doi:10.1016/j.pnpbp.2020.109976. PMID 32470498. S2CID 219104988.
  97. ^ a b Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, et al. (June 2012). "[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]" (PDF). Schmerz. 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID 22760463. Archived from the original (PDF) on 16 February 2013.
  98. ^ a b c "Management | Canadian Guidelines for the Diagnosis and Management of Fibromyalgia". Archived from the original on 11 June 2013.
  99. ^ Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL (October 2007). "Exercise for treating fibromyalgia syndrome". The Cochrane Database of Systematic Reviews (4): CD003786. doi:10.1002/14651858.CD003786.pub2. PMID 17943797.
  100. ^ a b c Andrade A, Dominski FH, Sieczkowska SM (December 2020). "What we already know about the effects of exercise in patients with fibromyalgia: An umbrella review". Seminars in Arthritis and Rheumatism. 50 (6): 1465–1480. doi:10.1016/j.semarthrit.2020.02.003. PMID 32147091. S2CID 212638860.
  101. ^ Martinsen S, Flodin P, Berrebi J, Löfgren M, Bileviciute-Ljungar I, Mannerkorpi K, et al. (May 2018). "The role of long-term physical exercise on performance and brain activation during the Stroop colour word task in fibromyalgia patients". Clinical Physiology and Functional Imaging. 38 (3): 508–516. doi:10.1111/cpf.12449. PMID 28627125. S2CID 36257462.
  102. ^ Cherry BJ, Weiss J, Barakat BK, Rutledge DN, Jones CJ (December 2009). "Physical performance as a predictor of attention and processing speed in fibromyalgia". Archives of Physical Medicine and Rehabilitation. 90 (12): 2066–2073. doi:10.1016/j.apmr.2009.07.011. PMID 19969170.
  103. ^ Munguía-Izquierdo D, Legaz-Arrese A (December 2008). "Assessment of the effects of aquatic therapy on global symptomatology in patients with fibromyalgia syndrome: a randomized controlled trial". Archives of Physical Medicine and Rehabilitation. 89 (12): 2250–2257. doi:10.1016/j.apmr.2008.03.026. PMID 19061736.
  104. ^ McLoughlin MJ, Stegner AJ, Cook DB (June 2011). "The relationship between physical activity and brain responses to pain in fibromyalgia". The Journal of Pain. 12 (6): 640–651. doi:10.1016/j.jpain.2010.12.004. PMC 3111901. PMID 21330218.
  105. ^ a b Valim V, Natour J, Xiao Y, Pereira AF, Lopes BB, Pollak DF, et al. (November 2013). "Effects of physical exercise on serum levels of serotonin and its metabolite in fibromyalgia: a randomized pilot study". Revista Brasileira de Reumatologia (in Spanish). 53 (6): 538–541. doi:10.1016/j.rbr.2013.02.001. PMID 24477734.
  106. ^ Genc A, Tur BS, Aytur YK, Oztuna D, Erdogan MF (July 2015). "Does aerobic exercise affect the hypothalamic-pituitary-adrenal hormonal response in patients with fibromyalgia syndrome?". Journal of Physical Therapy Science. 27 (7): 2225–2231. doi:10.1589/jpts.27.2225. PMC 4540854. PMID 26311959.
  107. ^ a b c d e f El-Shewy KM, Kunbaz A, Gad MM, Al-Husseini MJ, Saad AM, Sammour YM, Abdel-Daim MM (January 2019). "Hyperbaric oxygen and aerobic exercise in the long-term treatment of fibromyalgia: A narrative review". Biomedicine & Pharmacotherapy. 109: 629–638. doi:10.1016/j.biopha.2018.10.157. PMID 30399600. S2CID 53240356.
  108. ^ Andrade A, Vilarino GT, Sieczkowska SM, Coimbra DR, Steffens RA, Vietta GG (March 2018). "Acute effects of physical exercises on the inflammatory markers of patients with fibromyalgia syndrome: A systematic review". Journal of Neuroimmunology. 316: 40–49. doi:10.1016/j.jneuroim.2017.12.007. PMID 29254627. S2CID 46879701.
  109. ^ a b c d e f g Andrade A, Vilarino GT, Serafim TT, Pereira Júnior AA, de Souza CA, Sieczkowska SM (October 2019). "Modulation of Autonomic Function by Physical Exercise in Patients with Fibromyalgia Syndrome: A Systematic Review". PM & R. 11 (10): 1121–1131. doi:10.1002/pmrj.12158. PMID 30900831. S2CID 85448644.
  110. ^ a b Estévez-López F, Maestre-Cascales C, Russell D, Álvarez-Gallardo IC, Rodriguez-Ayllon M, Hughes CM, et al. (April 2021). "Effectiveness of Exercise on Fatigue and Sleep Quality in Fibromyalgia: A Systematic Review and Meta-analysis of Randomized Trials". Archives of Physical Medicine and Rehabilitation. 102 (4): 752–761. doi:10.1016/j.apmr.2020.06.019. PMID 32721388. S2CID 220847961.
  111. ^ McVeigh JG, Lucas A, Hurley DA, Basford JR, Baxter GD (September 2003). "Patients' perceptions of exercise therapy in the treatment of fibromyalgia syndrome: a survey". Musculoskeletal Care. 1 (2): 98–107. doi:10.1002/msc.45. PMID 20217670.
  112. ^ Barhorst EE, Andrae WE, Rayne TJ, Falvo MJ, Cook DB, Lindheimer JB (December 2020). "Elevated Perceived Exertion in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Meta-analysis". Medicine and Science in Sports and Exercise. 52 (12): 2615–2627. doi:10.1249/MSS.0000000000002421. PMID 32555018. S2CID 219918068.
  113. ^ a b c Russell D, Álvarez Gallardo IC, Wilson I, Hughes CM, Davison GW, Sañudo B, McVeigh JG (March 2018). "'Exercise to me is a scary word': perceptions of fatigue, sleep dysfunction, and exercise in people with fibromyalgia syndrome-a focus group study". Rheumatology International. 38 (3): 507–515. doi:10.1007/s00296-018-3932-5. PMID 29340774. S2CID 3395036.
  114. ^ Sanz-Baños Y, Pastor-Mira MÁ, Lledó A, López-Roig S, Peñacoba C, Sánchez-Meca J (October 2018). "Do women with fibromyalgia adhere to walking for exercise programs to improve their health? Systematic review and meta-analysis". Disability and Rehabilitation. 40 (21): 2475–2487. doi:10.1080/09638288.2017.1347722. PMID 28687050. S2CID 9032840.
  115. ^ Ryan S (2013). "Care of patients with fibromyalgia: assessment and management". Nursing Standard. 28 (13): 37–43. doi:10.7748/ns2013.11.28.13.37.e7722. PMID 24279570.
  116. ^ Bidonde J, Busch AJ, Schachter CL, Overend TJ, Kim SY, Góes SM, et al. (June 2017). "Aerobic exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 2017 (6): CD012700. doi:10.1002/14651858.cd012700. PMC 6481524. PMID 28636204.
  117. ^ a b Bidonde J, Busch AJ, Schachter CL, Webber SC, Musselman KE, Overend TJ, et al. (May 2019). "Mixed exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 5: CD013340. doi:10.1002/14651858.cd013340. PMC 6931522. PMID 31124142.
  118. ^ Kim SY, Busch AJ, Overend TJ, Schachter CL, van der Spuy I, Boden C, et al. (September 2019). "Flexibility exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 9: CD013419. doi:10.1002/14651858.CD013419. PMC 6718217. PMID 31476271.
  119. ^ Vilarino GT, Andreato LV, de Souza LC, Branco JH, Andrade A (November 2021). "Effects of resistance training on the mental health of patients with fibromyalgia: a systematic review". Clinical Rheumatology. 40 (11): 4417–4425. doi:10.1007/s10067-021-05738-z. PMID 33987785. S2CID 234489153.
  120. ^ Izquierdo-Alventosa R, Inglés M, Cortés-Amador S, Gimeno-Mallench L, Chirivella-Garrido J, Kropotov J, Serra-Añó P (May 2020). "Low-Intensity Physical Exercise Improves Pain Catastrophizing and Other Psychological and Physical Aspects in Women with Fibromyalgia: A Randomized Controlled Trial". International Journal of Environmental Research and Public Health. 17 (10): 3634. doi:10.3390/ijerph17103634. PMC 7277480. PMID 32455853.
  121. ^ a b c d da Silva JM, de Barros BS, Almeida GJ, O'Neil J, Imoto AM (March 2022). "Dosage of resistance exercises in fibromyalgia: evidence synthesis for a systematic literature review up-date and meta-analysis". Rheumatology International. 42 (3): 413–429. doi:10.1007/s00296-021-05025-9. PMID 34652480. S2CID 238991065.
  122. ^ Li H, Chen J, Xu G, Duan Y, Huang D, Tang C, Liu J (September 2020). "The Effect of Tai Chi for Improving Sleep Quality: A Systematic Review and Meta-analysis". Journal of Affective Disorders. 274: 1102–1112. doi:10.1016/j.jad.2020.05.076. PMID 32663938. S2CID 219743962.
  123. ^ Cheng CA, Chiu YW, Wu D, Kuan YC, Chen SN, Tam KW (October 2019). "Effectiveness of Tai Chi on fibromyalgia patients: A meta-analysis of randomized controlled trials". Complementary Therapies in Medicine. 46: 1–8. doi:10.1016/j.ctim.2019.07.007. PMID 31519264. S2CID 199039433.
  124. ^ Bidonde J, Busch AJ, Webber SC, Schachter CL, Danyliw A, Overend TJ, et al. (October 2014). "Aquatic exercise training for fibromyalgia". The Cochrane Database of Systematic Reviews (10): CD011336. doi:10.1002/14651858.cd011336. PMID 25350761.
  125. ^ Lima TB, Dias JM, Mazuquin BF, da Silva CT, Nogueira RM, Marques AP, et al. (October 2013). "The effectiveness of aquatic physical therapy in the treatment of fibromyalgia: a systematic review with meta-analysis". Clinical Rehabilitation. 27 (10): 892–908. doi:10.1177/0269215513484772. PMID 23818412. S2CID 25701866.
  126. ^ Perraton L, Machotka Z, Kumar S (November 2009). "Components of effective randomized controlled trials of hydrotherapy programs for fibromyalgia syndrome: A systematic review". Journal of Pain Research. 2: 165–173. doi:10.2147/JPR.S8052. PMC 3004626. PMID 21197303.
  127. ^ Galvão-Moreira LV, de Castro LO, Moura EC, de Oliveira CM, Nogueira Neto J, Gomes LM, Leal PD (July 2021). "Pool-based exercise for amelioration of pain in adults with fibromyalgia syndrome: A systematic review and meta-analysis". Modern Rheumatology. 31 (4): 904–911. doi:10.1080/14397595.2020.1829339. PMID 32990113. S2CID 222167851.
  128. ^ Bidonde J, Busch AJ, van der Spuy I, Tupper S, Kim SY, Boden C (September 2017). "Whole body vibration exercise training for fibromyalgia". The Cochrane Database of Systematic Reviews. 9: CD011755. doi:10.1002/14651858.cd011755.pub2. PMC 6483692. PMID 28950401.
  129. ^ "FDA Approves First Drug for Treating Fibromyalgia" (Press release). U.S. Food and Drug Administration. 21 June 2007. Archived from the original on 21 February 2008. Retrieved 14 January 2008.
  130. ^ European Medicines Agency. "Questions and answers on the recommendati on for the refusal of the marketing authorisation for Milnacipran Pierre Fabre Médicament/Impulsor" (PDF). European Medicines Agency. Archived (PDF) from the original on 22 February 2014. Retrieved 30 May 2013.
  131. ^ a b Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ (July 2015). "Amitriptyline for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 7 (7): CD008242. doi:10.1002/14651858.CD011824. PMC 6485478. PMID 26146793.
  132. ^ Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C (April 2012). "The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis". CNS Drugs. 26 (4): 297–307. doi:10.2165/11598970-000000000-00000. PMID 22452526. S2CID 207301478.
  133. ^ Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ (October 2015). "Milnacipran for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews (10): CD008244. doi:10.1002/14651858.CD008244.pub3. PMC 6481368. PMID 26482422.
  134. ^ a b Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W (February 2018). "Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia". The Cochrane Database of Systematic Reviews. 2 (7): CD010292. doi:10.1002/14651858.CD010292.pub2. PMC 5846183. PMID 29489029.
  135. ^ Welsch P, Bernardy K, Derry S, Moore RA, Häuser W (August 2018). "Mirtazapine for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 8: CD012708. doi:10.1002/14651858.CD012708.pub2. PMC 6513659. PMID 30080242.
  136. ^ Häuser W, Walitt B, Fitzcharles MA, Sommer C (January 2014). "Review of pharmacological therapies in fibromyalgia syndrome". Arthritis Research & Therapy. 16 (1): 201. doi:10.1186/ar4441. PMC 3979124. PMID 24433463.
  137. ^ Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W (June 2015). "Selective serotonin reuptake inhibitors for fibromyalgia syndrome". The Cochrane Database of Systematic Reviews (6): CD011735. doi:10.1002/14651858.cd011735. PMC 4755337. PMID 26046493.
  138. ^ a b c Tort S, Urrútia G, Nishishinya MB, Walitt B (April 2012). "Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome". The Cochrane Database of Systematic Reviews (4): CD009807. doi:10.1002/14651858.cd009807. PMID 22513976.
  139. ^ Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (2): CD007938. doi:10.1002/14651858.CD007938.pub4. PMC 6452908. PMID 28597471.
  140. ^ Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA (September 2016). "Pregabalin for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 9 (5): CD011790. doi:10.1002/14651858.CD011790.pub2. PMC 6457745. PMID 27684492.
  141. ^ Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ (June 2011). "Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response". BMC Musculoskeletal Disorders. 12: 125. doi:10.1186/1471-2474-12-125. PMC 3118156. PMID 21639874.
  142. ^ a b MacLean AJ, Schwartz TL (May 2015). "Tramadol for the treatment of fibromyalgia". Expert Review of Neurotherapeutics. 15 (5): 469–75. doi:10.1586/14737175.2015.1034693. PMID 25896486. S2CID 26613022.
  143. ^ Gaskell H, Moore RA, Derry S, Stannard C, et al. (Cochrane Pain, Palliative and Supportive Care Group) (September 2016). "Oxycodone for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2016 (9): CD012329. doi:10.1002/14651858.CD012329. PMC 6457853. PMID 27582266.
  144. ^ Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I (February 2018). "Combination pharmacotherapy for the treatment of fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2: CD010585. doi:10.1002/14651858.CD010585.pub2. PMC 6491103. PMID 29457627.
  145. ^ Goldenberg DL, Clauw DJ, Palmer RE, Clair AG (May 2016). "Opioid Use in Fibromyalgia: A Cautionary Tale". Mayo Clinic Proceedings (Review). 91 (5): 640–48. doi:10.1016/j.mayocp.2016.02.002. PMID 26975749.
  146. ^ Berger A. Patterns of use of opioids in patients with fibromyalgia In: EULAR; 2009:SAT0461
  147. ^ Staud R (August 2011). "Sodium oxybate for the treatment of fibromyalgia". Expert Opinion on Pharmacotherapy. 12 (11): 1789–98. doi:10.1517/14656566.2011.589836. PMID 21679091. S2CID 33026097.
  148. ^ See S, Ginzburg R (August 2008). "Choosing a skeletal muscle relaxant". American Family Physician. 78 (3): 365–70. PMID 18711953. Archived from the original on 1 April 2016.
  149. ^ Kaltsas G, Tsiveriotis K (2000). "Fibromyalgia". Endotext. MDText.com, Inc.
  150. ^ Heymann RE, Paiva Edos S, Helfenstein M Jr, Pollak DF, Martinez JE, Provenza JR, et al. (2010). "Brazilian consensus on the treatment of fibromyalgia". Revista Brasileira de Reumatologia. 50 (1): 56–66. doi:10.1590/S0482-50042010000100006. PMID 21125141.
  151. ^ Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, Moore RA (March 2017). "Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 3 (2): CD012332. doi:10.1002/14651858.CD012332.pub2. PMC 6464559. PMID 28349517.
  152. ^ Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W (June 2016). "Antipsychotics for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2016 (6): CD011804. doi:10.1002/14651858.cd011804.pub2. PMC 6457603. PMID 27251337.
  153. ^ Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W (July 2016). "Cannabinoids for fibromyalgia". The Cochrane Database of Systematic Reviews. 7: CD011694. doi:10.1002/14651858.cd011694.pub2. PMC 6457965. PMID 27428009.
  154. ^ Younger J, Parkitny L, McLain D (April 2014). "The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain". Clinical Rheumatology. 33 (4): 451–59. doi:10.1007/s10067-014-2517-2. PMC 3962576. PMID 24526250.
  155. ^ Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (27 April 1998). "Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis". The Cochrane Database of Systematic Reviews (2): CD000953. doi:10.1002/14651858.cd000953. PMC 7032888. PMID 10796395.
  156. ^ Deare JC, Zheng Z, Xue CC, Liu JP, Shang J, Scott SW, Littlejohn G (May 2013). "Acupuncture for treating fibromyalgia". The Cochrane Database of Systematic Reviews (5): CD007070. doi:10.1002/14651858.CD007070.pub2. PMC 4105202. PMID 23728665.
  157. ^ Haddad HW, Mallepalli NR, Scheinuk JE, Bhargava P, Cornett EM, Urits I, Kaye AD (December 2021). "The Role of Nutrient Supplementation in the Management of Chronic Pain in Fibromyalgia: A Narrative Review". Pain and Therapy. 10 (2): 827–848. doi:10.1007/s40122-021-00266-9. PMC 8586285. PMID 33909266.
  158. ^ Mehrabani S, Askari G, Miraghajani M, Tavakoly R, Arab A (April 2019). "Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies". Complementary Therapies in Medicine. 43: 181–187. doi:10.1016/j.ctim.2019.01.022. PMID 30935528. S2CID 86467031.
  159. ^ Hargreaves IP, Mantle D (2021). Guest PC (ed.). "Targeted Treatment of Age-Related Fibromyalgia with Supplemental Coenzyme Q10". Advances in Experimental Medicine and Biology. Cham: Springer International Publishing. 1286: 77–85. doi:10.1007/978-3-030-55035-6_5. ISBN 978-3-030-55034-9. PMID 33725346. S2CID 232261388.
  160. ^ Hemati K, Amini Kadijani A, Sayehmiri F, Mehrzadi S, Zabihiyeganeh M, Hosseinzadeh A, Mirzaei A (February 2020). "Melatonin in the treatment of fibromyalgia symptoms: A systematic review". Complementary Therapies in Clinical Practice. 38: 101072. doi:10.1016/j.ctcp.2019.101072. PMID 31783341. S2CID 208497324.
  161. ^ Aziz I, Hadjivassiliou M, Sanders DS (September 2015). "The spectrum of noncoeliac gluten sensitivity". Nature Reviews. Gastroenterology & Hepatology. 12 (9): 516–526. doi:10.1038/nrgastro.2015.107. PMID 26122473. S2CID 2867448.
  162. ^ Isasi C, Colmenero I, Casco F, Tejerina E, Fernandez N, Serrano-Vela JI, et al. (November 2014). "Fibromyalgia and non-celiac gluten sensitivity: a description with remission of fibromyalgia". Rheumatology International. 34 (11): 1607–1612. doi:10.1007/s00296-014-2990-6. PMC 4209093. PMID 24728027.
  163. ^ Rodrigo L, Blanco I, Bobes J, de Serres FJ (August 2014). "Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study". Arthritis Research & Therapy. 16 (4): 421. doi:10.1186/s13075-014-0421-4. PMC 4177310. PMID 25160886.
  164. ^ Nadal-Nicolás Y, Miralles-Amorós L, Martínez-Olcina M, Sánchez-Ortega M, Mora J, Martínez-Rodríguez A (May 2021). "Vegetarian and Vegan Diet in Fibromyalgia: A Systematic Review". International Journal of Environmental Research and Public Health. 18 (9): 4955. doi:10.3390/ijerph18094955. PMC 8125538. PMID 34066603.
  165. ^ Arnold LM, Gebke KB, Choy EH (February 2016). "Fibromyalgia: management strategies for primary care providers". International Journal of Clinical Practice. 70 (2): 99–112. doi:10.1111/ijcp.12757. PMC 6093261. PMID 26817567.
  166. ^ a b Okifuji A, Hare BD (December 2013). "Management of fibromyalgia syndrome: review of evidence". Pain and Therapy. 2 (2): 87–104. doi:10.1007/s40122-013-0016-9. PMC 4107911. PMID 25135147.
  167. ^ Williams AC, Fisher E, Hearn L, Eccleston C (August 2020). "Psychological therapies for the management of chronic pain (excluding headache) in adults". The Cochrane Database of Systematic Reviews. 8 (5): CD007407. doi:10.1002/14651858.CD007407.pub4. PMC 7437545. PMID 32794606.
  168. ^ Arnold LM, Clauw DJ, Dunegan LJ, Turk DC (May 2012). "A framework for fibromyalgia management for primary care providers". Mayo Clinic Proceedings. 87 (5): 488–96. doi:10.1016/j.mayocp.2012.02.010. PMC 3498162. PMID 22560527.
  169. ^ a b c Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG (November 2010). "Psychological treatments for fibromyalgia: a meta-analysis". Pain. 151 (2): 280–95. doi:10.1016/j.pain.2010.06.011. PMID 20727679. S2CID 10513179.
  170. ^ Smith HS, Barkin RL (2011). "Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy". American Journal of Therapeutics. 17 (4): 418–39. doi:10.1097/MJT.0b013e3181df8e1b. PMID 20562596. S2CID 8466671.
  171. ^ Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W (September 2013). "Cognitive behavioural therapies for fibromyalgia". The Cochrane Database of Systematic Reviews. 9 (9): CD009796. doi:10.1002/14651858.CD009796.pub2. PMC 6481397. PMID 24018611.
  172. ^ Bernardy K, Füber N, Köllner V, Häuser W (October 2010). "Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome – a systematic review and meta-analysis of randomized controlled trials". The Journal of Rheumatology. 37 (10): 1991–2005. doi:10.3899/jrheum.100104. PMID 20682676. S2CID 11357808.
  173. ^ Mohabbat AB, Mahapatra S, Jenkins SM, Bauer BA, Vincent A, Wahner-Roedler DL (December 2019). "Use of Complementary and Integrative Therapies by Fibromyalgia Patients: A 14-Year Follow-up Study". Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 3 (4): 418–428. doi:10.1016/j.mayocpiqo.2019.07.003. PMC 6978595. PMID 31993560.
  174. ^ Theadom A, Cropley M, Smith HE, Feigin VL, McPherson K (April 2015). "Mind and body therapy for fibromyalgia". The Cochrane Database of Systematic Reviews. 2015 (4): CD001980. doi:10.1002/14651858.CD001980.pub3. PMC 8409283. PMID 25856658.
  175. ^ Johnson MI, Claydon LS, Herbison GP, Jones G, Paley CA, et al. (Cochrane Pain, Palliative and Supportive Care Group) (October 2017). "Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2017 (10): CD012172. doi:10.1002/14651858.CD012172.pub2. PMC 6485914. PMID 28990665.
  176. ^ a b c Gibson, William; Wand, Benedict M.; Meads, Catherine; Catley, Mark J.; O'Connell, Neil E. (3 April 2019). "Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 4: CD011890. doi:10.1002/14651858.CD011890.pub3. ISSN 1469-493X. PMC 6446021. PMID 30941745.
  177. ^ Dailey DL, Vance CG, Rakel BA, Zimmerman MB, Embree J, Merriwether EN, et al. (May 2020). "Transcutaneous Electrical Nerve Stimulation Reduces Movement-Evoked Pain and Fatigue: A Randomized, Controlled Trial". Arthritis & Rheumatology. 72 (5): 824–836. doi:10.1002/art.41170. PMC 7188591. PMID 31738014.
  178. ^ a b c Choo YJ, Kwak SG, Chang MC (January 2022). "Effectiveness of Repetitive Transcranial Magnetic Stimulation on Managing Fibromyalgia: A Systematic Meta-Analysis". Pain Medicine: pnab354. doi:10.1093/pm/pnab354. PMID 34983056.
  179. ^ a b c Sun P, Fang L, Zhang J, Liu Y, Wang G, Qi R (March 2022). "Repetitive Transcranial Magnetic Stimulation for Patients with Fibromyalgia: A Systematic Review with Meta-Analysis". Pain Medicine. 23 (3): 499–514. doi:10.1093/pm/pnab276. PMID 34542624.
  180. ^ a b [unreliable medical source?] Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Häuser W, Wolfe F (October 2011). "The longitudinal outcome of fibromyalgia: a study of 1555 patients". The Journal of Rheumatology. 38 (10): 2238–2246. doi:10.3899/jrheum.110026. PMID 21765102. S2CID 207672626.
  181. ^ a b c [unreliable medical source?] Kashikar-Zuck S, Cunningham N, Peugh J, Black WR, Nelson S, Lynch-Jordan AM, et al. (February 2019). "Long-term outcomes of adolescents with juvenile-onset fibromyalgia into adulthood and impact of depressive symptoms on functioning over time". Pain. 160 (2): 433–441. doi:10.1097/j.pain.0000000000001415. PMC 6344278. PMID 30335681.
  182. ^ Leino-Arjas P, Rajaleid K, Mekuria G, Nummi T, Virtanen P, Hammarström A (January 2018). "Trajectories of musculoskeletal pain from adolescence to middle age: the role of early depressive symptoms, a 27-year follow-up of the Northern Swedish Cohort". Pain. 159 (1): 67–74. doi:10.1097/j.pain.0000000000001065. PMID 28937577. S2CID 22164186.
  183. ^ Health Information Team (February 2004). "Fibromyalgia". BUPA insurance. Archived from the original on 22 June 2006. Retrieved 24 August 2006.
  184. ^ Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL (August 1981). "Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls". Seminars in Arthritis and Rheumatism. 11 (1): 151–71. doi:10.1016/0049-0172(81)90096-2. PMID 6944796.
  185. ^ "Fibro-". Dictionary.com. Archived from the original on 13 December 2009. Retrieved 21 May 2008.
  186. ^ "Meaning of myo". 12 April 2009. Archived from the original on 12 April 2009. Retrieved 26 August 2012.
  187. ^ "Meaning of algos". 12 April 2009. Archived from the original on 12 April 2009. Retrieved 26 August 2012.
  188. ^ a b Wolfe F (April 2009). "Fibromyalgia wars". The Journal of Rheumatology. 36 (4): 671–78. doi:10.3899/jrheum.081180. PMID 19342721. S2CID 2091976.
  189. ^ Smythe HA, Moldofsky H (1977). "Two contributions to understanding of the "fibrositis" syndrome". Bulletin on the Rheumatic Diseases. 28 (1): 928–31. PMID 199304.
  190. ^ Winfield JB (June 2007). "Fibromyalgia and related central sensitivity syndromes: twenty-five years of progress". Seminars in Arthritis and Rheumatism. 36 (6): 335–38. doi:10.1016/j.semarthrit.2006.12.001. PMID 17303220.
  191. ^ a b Inanici F, Yunus MB (October 2004). "History of fibromyalgia: past to present". Current Pain and Headache Reports. 8 (5): 369–78. doi:10.1007/s11916-996-0010-6. PMID 15361321. S2CID 42573740.
  192. ^ Goldenberg DL (May 1987). "Fibromyalgia syndrome. An emerging but controversial condition". JAMA. 257 (20): 2782–87. doi:10.1001/jama.257.20.2782. PMID 3553636.
  193. ^ Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. (February 1990). "The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee". Arthritis and Rheumatism. 33 (2): 160–72. doi:10.1002/art.1780330203. PMID 2306288.
  194. ^ "High health care utilization and costs in patients with fibromyalgia". Drug Benefit Trends. 22 (4): 111. 2010. Archived from the original on 29 October 2012. Retrieved 14 June 2010.
  195. ^ Berenson A (14 January 2008). "Drug Approved. Is Disease Real?". The New York Times. Archived from the original on 10 May 2015. Retrieved 26 March 2014.
  196. ^ "Fibromyalgia: An interview with Dr Frederick Wolfe, University of Kansas School of Medicine". 22 March 2013. Archived from the original on 29 May 2014. Retrieved 28 May 2014.
  197. ^ Goldenberg DL (January 1995). "Fibromyalgia: why such controversy?". Annals of the Rheumatic Diseases. 54 (1): 3–5. doi:10.1136/ard.54.1.3. PMC 1005499. PMID 7880118.
  198. ^ Yunus MB (June 2007). "Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes". Seminars in Arthritis and Rheumatism. 36 (6): 339–356. doi:10.1016/j.semarthrit.2006.12.009. PMID 17350675.

External links[edit]

Leave a Reply